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Abstract
FDA to Create Drug Safety Board In February 2005, the Food and Drug Ad-
ministration (FDA) announced that it will create a new independent Drug Safety
Oversight Board (DSB) to oversee the management of drug safety issues within
the Center for Drug Evaluation and Research (CDER). The FDA Commissioner
will appoint individuals from the FDA and medical experts from other Health and
Human Services agencies and government departments to the DSB, which also
will consult with other medical experts and patient and consumer group repre-
sentatives. Additionally, the FDA is proposing a new “Drug Watch” web page
for emerging data and risk information, and anticipates an increased use of infor-
mation sheets written for healthcare professionals and patients. Because of the
potential concerns associated with disseminating emerging information prior to
regulatory action, the agency has stated it will solicit public input. The FDA will
issue draft guidance on procedures and criteria for identifying drugs and informa-
tion for the Drug Watch web page.
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FDA to Create Drug Safety Board
In February 2005, the Food and Drug 
Administration (FDA) announced that it 
will create a new independent Drug Safety 
Oversight Board (DSB) to oversee the 
management of drug safety issues within the 
Center for Drug Evaluation and Research 
(CDER). The FDA Commissioner will appoint 
individuals from the FDA and medical experts 
from other Health and Human Services 
agencies and government departments to 
the DSB, which also will consult with other 
medical experts and patient and consumer 
group representatives. Additionally, the FDA 
is proposing a new “Drug Watch” web page 
for emerging data and risk information, and 
anticipates an increased use of information 
sheets written for healthcare professionals and 
patients. Because of the potential concerns 
associated with disseminating emerging 
information prior to regulatory action, 
the agency has stated it will solicit public 
input. The FDA will issue draft guidance on 
procedures and criteria for identifying drugs and 
information for the Drug Watch web page. 
The agency’s announcement falls on the heels 
of earlier action also taken to address drug 
safety concerns. In November 2004, Acting 
FDA Commissioner Lester M. Crawford, D.V.M., 
Ph.D., announced that an Institute of Medicine 
committee would study the effectiveness of 
the US drug safety system and determine 
if additional steps could be taken to learn 
more about the side effects of drugs as they 
are actually used. Dr. Crawford announced a 
CDER pilot program to provide for a review 
of differing professional opinions by FDA and 
outside experts. The agency will also conduct 
workshops and advisory committee meetings 
to discuss drug safety and risk management 
issues, such as whether a safety concern alters 
a drug’s risk to beneﬁt balance; whether the 
agency should request that a sponsor conduct a 
study to address an issue and, if so, what type of 
study would be most appropriate; and whether 
a ﬁnding is unique to one product or reﬂects a 
drug class effect. These meetings are designed 
to include a broad array of participants, 
including experts from academia, the pharma-
ceutical industry and the healthcare community.
FDA Factsheet
FDA Statement
OVERHAUL OF EUROPE
Overhaul of EU Pharmaceutical Law
Nine years ago, the European Parliament 
stated that in order for the EU to remain 
competitive in the expanding European 
and international non-proprietary markets, 
measures should be introduced at the EU 
level permitting generic pharmaceutical 
companies to initiate experiments and 
regulatory preparations prior to patent and 
supplementary protection certiﬁcate expiration, 
although the marketing of their products 
should not be permitted until after this date. 
As a result, by the end of November 2005, 
the EU pharmaceutical legislative landscape 
shall have witnessed signiﬁcant changes. One 
new regulation and three new directives shall 
enter into force effecting approximately 200 
alterations, ranging from deﬁnition and admini- 
stration clariﬁcations to substantial alterations 
to the approval process for generic products 
and follow-on biologicals (biosimilars). 
Alterations to the regulatory powers of the 
relevant authorities and a widening of the 
mandatory scope of the centralized procedure 
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shall take place, in addition to stricter phar-
macovigilance and increased transparency.
These amendments shall permit the ﬁling of 
abridged applications for generic medicinal 
products eight years after EU approval of 
the reference product (although marketing 
is restricted until after ten years—or eleven 
in the case of a new therapeutic indication of 
signiﬁcant clinical beneﬁt). The present reliance 
on the “essentially similar” test comparing a 
generic medicinal product to one previously 
authorized has been replaced with a codiﬁed 
deﬁnition of a “generic medicinal product”—one 
that has the same qualitative and quantitative 
active substance composition, the same 
pharmaceutical form, and is bioequivalent. 
Finally, the Committee for Human Medicinal 
Products technical guidelines must be taken into 
account by marketing authorization applicants. 
Regulation on Medicinal Products for 
Human and Veterinary Use
Directive on Medicinal Products for Human Use
Directive on Veterinary Medicinal Products
Directive on Medicinal Products for 
Human Use (Herbal Products)
ECJ Rulings Erode Data Exclusivity 
While the new EU Pharmaceutical Package 
outlined above clariﬁes the deﬁnition of a 
generic medicinal product for the purpose of 
abridged applications ﬁled after the provisions 
enter into force, present applications rely on 
the outcome of two recent European Court 
of Justice (ECJ) rulings, the joint effect of which 
has been to further erode the reliance on 
regulatory data protection afforded to newly 
authorized medicines. In separate references 
concerning Eli Lilly and SmithKline Beecham, 
the ECJ held that “essentially similar” is satisﬁed 
respectively, by a medicinal product differing 
only in pharmaceutical form and one sharing 
the same therapeutic moiety, but differing 
as to the identity of its combined salt. 
Approved Prescription Services v. UK Licensing 
Authority (Interested Party: Eli Lilly)
SmithKline Beecham v. Laegemiddelstyrelsen 
(Interveners: Synthon and Genthon)
INTELLECTUAL PROPERTY
UNITED STATES 
Life Cycle Management and Proposed 
Patent Harmonization
The growth of the generic drug industry began 
with the enactment of the Hatch-Waxman Act 
in 1984. With the rise of generic competition, 
innovator drug companies embarked on 
creative patent strategies, tactical licensing 
arrangements and litigation intended to protect 
their market exclusivity of brand name drugs. 
All of these considerations—together with 
an understanding of the complex body of 
statutes, regulations and court decisions that 
control practice under the Hatch-Waxman 
Act—are vital in mapping a course for life cycle 
management of a drug product. Reﬁnements 
and changes to the Hatch-Waxman Act 
continue to inﬂuence innovator drug companies’ 
strategies for product life cycle management. 
The Medicare Prescription Drug, Improvement 
and Modernization Act of 2003 (Medicare 
Amendment) made a number of important 
changes to the Hatch-Waxman Act, including 
limiting the number of automatic 30-month 
stays to one and eliminating the district court 
decision trigger for 180-day generic marketing 
exclusivity. Prior to the Medicare Amendment, 
the FDA implemented guidelines clarifying what 
patents could be listed in the Orange Book. 
Implementation of strategies for product life cycle 
management starts long before the expiration 
of the basic patent covering the innovator drug. 
But the principal strategy of maintaining patent 
protection through a stream of patentable 
product innovations faces the constant hurdle of 
shifting patent laws and regulations. Potentially 
sweeping changes to fundamental laws of the US 
patent system are on the horizon. The National 
Academies’ Board on Science, Technology 
and Economic Policy (STEP) and the Federal 
Trade Commission (FTC) issued reports with 
recommendations on modernizing US patent 
law. A singularly important recommendation 
of STEP is to seek greater harmonization 
between US patent laws and those of other 
countries, including changing US patent law 
to guarantee the right to patent to the ﬁrst 
inventor who ﬁles for a patent, and creating a 
window after a patent is issued for an opposition 
procedure that would permit the correction 
of any mistake made in granting the patent.
STEP Report
FTC Report
“By the end of 
November 2005, the 
EU pharmaceutical 
legislative landscape 
shall have witnessed 
signiﬁcant changes.”
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EUROPE 
Patent Claim Construction Guidance 
from the House of Lords
The October 2004 Kirin-Amgen v. TKT judgment 
is signiﬁcant for intellectual property practitioners 
operating in biotech and high-tech industries. 
Adjudicating on a European patent relating to 
inter-cellular production of erythropoietin, the 
House of Lords conducted a detailed review of 
the law on claim construction and conﬁrmed 
that the principle of “purposive construction” 
was in accordance with the European Patent 
Convention. Their lordships continued to 
state that this did not, however, mean that the 
rigid application of certain formulations of this 
principle were appropriate in the biotech and 
high-tech ﬁelds. The critical question was what 
the skilled man would have understood as being 
intended by the language used in the claim. 
Kirin-Amgen v. TKT (2004)
Interim Injunctions against Generics Refused
In two separate applications during the close 
of 2004, the UK High Court refused interim 
injunctions against generic pharmaceutical 
companies alleged to infringe European patents 
for crystalline clarithromycin and the cancer 
treatment paclitaxel, respectively. The ﬁrst 
was refused on the basis of the “manifest 
weakness of the patent” (although the court 
noted that had the facts been contrary, the 
“big unquantiﬁable” loss represented by “price 
erosion” would have outweighed the “little 
unquantiﬁable” loss represented by the generic’s 
“ﬁve months’ advantage” in the market). The 
second was refused because of incomplete 
evidence and the absence of sufﬁcient threat and 
damage to require urgent court intervention. 
Abbott v. Ranbaxy (2004)
Mayne v. Teva (2004)
German Patent Act Amendment
Effective on February 28, 2005, the German 
Patent Act shall ﬁnally be updated to 
accord with the European Directive on the 
legal protection of biotech inventions. Of 
particular interest, the German legislature 
has decided that only inventions regarding 
precisely described commercial applications 
of human gene sequences and their cor-
responding protein may be patentable.
Directive on Legal Protection of Biotech Inventions
German Patent Act
Introduction of EU “Bolar” Provision
By the end of 2005, all EU Member States 
must have implemented the EU Pharmaceutical 
Regulation and Directives Package. This shall 
permit pre-patent-expiration development 
work, registration and generic approval, and 
non-infringing testing of patented medicines.
ANTITRUST/COMPETITION
UNITED STATES
FTC Supports Generic’s Petition to Expand 
Availability of Declaratory Judgment Actions
The US Federal Trade Commission has ﬁled a 
brief in support of the efforts of a generic drug 
manufacturer (Teva) to seek further review of a 
decision of the Court of Appeals for the Federal 
Circuit, which blocked its effort to market an 
alternative to the antidepressant drug Zoloft and 
sided with Zoloft’s manufacturer, Pﬁzer. Under 
the Hatch-Waxman Act—a complex statute 
which governs the rights of manufacturers of 
brand and generic drugs—the ﬁrst generic 
manufacturer to ﬁle a “Paragraph IV certiﬁcation” 
challenging the brand drug manufacturer’s 
patent obtains a period of 180 days of marketing 
“exclusivity,” during which the FDA may not 
approve subsequent generic versions of the 
drug. However, the period does not begin to 
run until the ﬁrst day of commercial marketing 
by the generic manufacturer or the date of a 
court decision ﬁnding the patent is invalid or 
not infringed. Thus, a “bottleneck” may be 
created where the generic manufacturer and 
the patent owner reach a settlement under 
which the generic manufacturer agrees to 
delay market entry in exchange for a license 
to the patent. The generic manufacturer 
still has the right to 180 days of exclusivity, 
but the period does not begin to run and 
subsequent generics thus cannot be approved.
In this case, Pﬁzer reached such a settlement with 
Ivax (the ﬁrst generic manufacturer to challenge 
its patent), and Teva (the second generic 
manufacturer) sought to break the bottleneck by 
ﬁling its own Paragraph IV certiﬁcation. When 
Pﬁzer did not sue Teva, the company then sought 
a declaratory judgment that Pﬁzer’s patent was 
invalid or not infringed. However, the lower court 
held that there was no “actual controversy” 
between the parties (which is required to bring 
a declaratory judgment suit) because there was 
no present threat that Pﬁzer would sue Teva 
for infringement. The appellate court upheld 
“The critical question was 
what the skilled man 
would have understood 
by the language 
used in the claim.”
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the decision and Teva is now seeking rehearing 
and/or review before the full “en banc” court. 
Essentially, the FTC has sided with Teva on 
public policy grounds, arguing that, in this 
context, declaratory judgment actions should 
be allowed to proceed because they “could 
play an important role in furthering competitive 
pharmaceutical markets and in lowering 
healthcare costs.” The FTC has previously 
supported challenges (and has brought them 
itself ) to what it believes to be abuses of the 
Hatch-Waxman Act’s provisions that impede 
competition by generic manufacturers. 
FTC Brief
EUROPE
Advocate-General Opinion on Supply 
Restrictions That Limit Parallel Trade
In October 2004, Advocate-General Jacobs 
delivered an important opinion in Syfait v. 
GlaxoSmithKline. This was a reference to the 
European Court of Justice from the Greek 
Competition Commission on the issue of 
whether the protection of legitimate commercial 
interests can justify a restriction of supply by 
a dominant pharmaceutical company, which 
is designed to limit parallel trade. Advocate-
General Jacobs considered that a refusal to 
supply does not automatically amount to 
an abuse of a dominant position within the 
meaning of Article 82 EC simply because the 
measure is designed to restrict parallel trade. 
Instead, he considered that a supply restriction 
that limits parallel trade can be objectively 
justiﬁed in the “highly speciﬁc” context of 
the European pharmaceutical industry as: 
(1) normal competitive conditions do not 
exist in the European pharmaceutical 
market due to the high level of regulation 
which affects price and distribution; 
(2)  incentives for dominant companies to 
innovate and invest in R&D would be 
harmed if prices to wholesalers across the 
EU were effectively reduced to the lowest 
national price charged to wholesalers; and 
(3)  parallel trade in pharmaceuticals mainly 
beneﬁts wholesalers, rather than purchasers. 
The opinion of the Advocate-General is not 
binding on the European Court of Justice, whose 
ﬁnal judgment is still awaited, although such 
opinions are upheld in a large majority of cases.
Syfait v. GlaxoSmithKline (2004)
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